Related Experiment Videos
Management of multiple myeloma
1Department of Haematology, CHU Nantes, France. jlharousseau@sante.univnantes.fr
Reviews in Clinical and Experimental Hematology
|March 6, 2003
Summary
Recent advancements have transformed multiple myeloma (MM) treatment, with high-dose therapy and stem cell transplantation offering superior outcomes for younger patients. Innovative strategies like thalidomide and prognostic factor analysis are further refining MM management.
Area of Science:
- Hematology
- Oncology
- Clinical Therapeutics
Background:
- Multiple myeloma (MM) treatment has seen limited progress, with traditional chemotherapy showing no survival advantage over melphalan-prednisone.
- Recent innovations over the past 15 years have significantly altered MM management paradigms.
Purpose of the Study:
- To review and summarize innovative therapeutic strategies in multiple myeloma management.
- To highlight advancements in high-dose therapy, stem cell transplantation, supportive care, and novel agents.
Main Methods:
- Review of recent clinical trials and meta-analyses in multiple myeloma.
- Analysis of data on high-dose therapy with autologous stem cell transplantation (ASCT).
- Evaluation of bisphosphonates, recombinant erythropoietin, and thalidomide in MM treatment.
Main Results:
- High-dose therapy with ASCT is superior to conventional chemotherapy for younger MM patients.
- Bisphosphonates reduce skeletal events; erythropoietin decreases transfusion needs, improving quality of life.
- Thalidomide, alone or with dexamethasone, shows high response rates and is under evaluation for front-line therapy.
Conclusions:
- Innovative strategies, including ASCT and novel agents like thalidomide, have dramatically improved MM management.
- Prognostic factors (e.g., beta 2 microglobulin, cytogenetics) aid in tailoring therapeutic strategies for distinct patient subgroups.
- Ongoing research focuses on optimizing ASCT and integrating new therapies for better MM outcomes.